Tedalinab
Tedalinab (GRC-10693) is a potent, orally active, and selective cannabinoid receptor 2 (CB2) agonist. Tedalinab has >4700-fold functional selectivity for CB2 over CB1. Tedalinab has potential for neuropathic pain and osteoarthritis treatment[1].
Product Specifications
CAS Number
916591-01-0
Product Name Alternative
GRC-10693
UNSPSC
12352005
Target
Cannabinoid Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/tedalinab.html
Purity
99.94
Solubility
DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(C1=NN(C2=CC=C(F)C=C2F)C3=C1[C@@]4([H])CC[C@]3([H])C4)NC(C)(C)C
Molecular Formula
C19H21F2N3O
Molecular Weight
345.39
References & Citations
[1]Glenmark’s molecule for neuropathic pain, osteoarthritis - GRC 10693, successfully completes Phase I trials.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
CB2
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Lentiviral human HECTD4 shRNA (UAS) - Lentiviral human HECTD4 shRNA (UAS, RFP) (25)
Recombinant Synechococcus sp. UPF0133 protein CYA_1369 (CYA_1369)